HDAC6 as a target for antileukemic drugs in acute myeloid leukemia

Leukemia Research

Volumn 36, Issue 8, 2012, Pages 1055-1062

  Hackanson, Björn ^a   Rimmele, Leander ^a   Benkißer, Marco ^a,b   Abdelkarim, Mahmoud ^a   Fliegauf, Manfred ^a   Jung, Manfred ^b   Lübbert, Michael ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Acute myeloid leukemia; Histone deacetylase inhibitors; Therapy

Indexed keywords

2 (7 HYDROXYCARBAMOYLHEPATNOYL AMINO) 3 [1,1':4',1'']TERPHENYL 4 YLPROPIONIC ACID METHYLESTER; 2 (9 HYDROXYCARBAMOYLNONANOYL AMINO) 3 PHENYLPROPIONIC ACID METHYLESTER; 4 [2 (5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 2 NAPHTHYL)VINYL]BENZOIC ACID; [3 (4 FURAN 2 YLPHENYL) 2 7 HYDROXYCARBOMOYL HEPTANOYLAMINO] PROPIONIC ACID METHYLESTER; ALPHA TUBULIN; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 1; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; HISTONE H4; ST 13; ST 34; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOACCUMULATION; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; EX VIVO STUDY; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; IN VITRO STUDY; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN TARGETING;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HL-60 CELLS; HUMANS; JURKAT CELLS; K562 CELLS; LEUKEMIA, MYELOID, ACUTE; MOLECULAR TARGETED THERAPY; TIME FACTORS; U937 CELLS;

EID: 84862548703     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.02.026     Document Type: Article

References (35)

1. Lübbert M., Suciu S., Baila L., Rüter B.H., Platzbecker U., Giagounidis A., et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 2011, April 11 [Epub ahead of print].
2. Lübbert M, Rüter BH, Claus R, Schmoor C, Schmid M, Germing U et al. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica 2011:97:393-401.
3. Fenaux P., Mufti G.J., Hellström-Lindberg E., Santini V., Gattermann N., Germing U., et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010, 28:562-569.
4. Haberland M., Montgomery R.L., Olson E.N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 2009, 10:32-42.
5. Haberland M., Johnson A., Mokalled M.H., Montgomery R.L., Olson E.N. Genetic dissection of histone deacetylase requirement in tumor cells. Proc Natl Acad Sci U S A 2009, 106:7751-7755.
6. Aldana-Masangkay G.I., Sakamoto K.M. The role of HDAC6 in cancer. J Biomed Biotechnol 2011, 2011:875824.
7. Schemies J., Sippl W., Jung M. Histone deacetylase inhibitors that target tubulin. Cancer Lett 2009, 280:222-232.
8. Yang Y., Rao R., Shen J., Tang Y., Fiskus W., Nechtman J., et al. Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion. Cancer Res 2008, 68:4833-4842.
9. Hideshima T., Bradner J.E., Wong J., Chauhan D., Richardson P., Schreiber S.L., et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A 2005, 102:8567-8572.
10. Krämer O.H., Zhu P., Ostendorff H.P., Golebiewski M., Tiefenbach J., Peters M.A., et al. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J 2003, 22:3411-3420.
11. Fiskus W., Ren Y., Mohapatra A., Bali P., Mandawat A., Rao R., et al. Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. Clin Cancer Res 2007, 13:4882-4890.
12. Kekatpure V.D., Dannenberg A.J., Subbaramaiah K. HDAC6 modulates Hsp90 chaperone activity and regulates activation of aryl hydrocarbon receptor signaling. J Biol Chem 2009, 284:7436-7445.
13. Boyault C., Zhang Y., Fritah S., Caron C., Gilquin B., Kwon S.H., et al. HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates. Genes Dev 2007, 21:2172-2181.
14. Palijan A., Fernandes I., Bastien Y., Tang L., Verway M., Kourelis M., et al. Function of Histone deacetylase 6 as a cofactor of nuclear receptor coregulator LCoR. J Biol Chem 2009, 284:30275-30287.
15. Scott G.K., Marx C., Berger C.E., Saunders L.R., Verdin E., Schäfer S., et al. Destabilization of ERBB2 transcripts by targeting 3' untranslated region messenger RNA associated HuR and histone deacetylase-6. Mol Cancer Res 2008, 6:1250-1258.
16. Haggarty S.J., Koeller K.M., Wong J.C., Grozinger C.M., Schreiber S.L. Domain-selective small molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci U S A 2003, 100:4389-4394.
17. Butler K.V., Kalin J., Brochier C., Vistoli G., Langley B., Kozikowski A.P., et al. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J Am Chem Soc 2010, 132:10842-10846.
18. Schäfer S., Saunders L., Eliseeva E., Velena A., Jung M., Schwienhorst A., et al. Phenylalanine-containing hydroxamic acids as selective inhibitors of class IIb histone deacetylases (HDACs). Bioorg Med Chem 2008, 16:2011-2033.
19. Dryden S.C., Nahhas F.A., Nowak J.E., Goustin A.S., Tainsky M.A. Role for human SIRT2 NAD-dependent deacetylase activity in control of mitotic exit in the cell cycle. Mol Cell Biol 2003, 23:3173-3185.
20. Pellegrini F., Budman D.R. Review: tubulin function, action of antitubulin drugs, and new drug development. Cancer Invest 2005, 23:264-273.
21. Tran A.D., Marmo T.P., Salam A.A., Che S., Finkelstein E., Kabarriti R., et al. HDAC6 deacetylation of tubulin modulates dynamics of cellular adhesion. J Cell Sci 2007, 120:469-479.
22. Bradbury C.A., Khanim F.L., Hayden R., Bunce C.M., White D.A., Drayson M.T., et al. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 2006, 19:1751-1759.
23. Chou C.J., Herman D., Gottesfeld J.M. Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases. J Biol Chem 2008, 283:35402-36359.
24. Beckers T., Burkhardt C., Wieland H., Gimmnich P., Ciossek T., Maier T., et al. Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int J Cancer 2007, 121:1138-1148.
25. Hu× C., Guardiola A., Shao R., Kawaguchi Y., Ito A., Nixon A., et al. HDAC6 is a microtubule-associated deacetylase. Nature 2002, 417:455-458.
26. Rao R., Fiskus W., Yang Y., Lee P., Joshi R., Fernandez P., et al. HDAC6 inhibition enhances 17-AAG-mediated abrogation of hsp90 chaperone function in human leukemia cells. Blood 2008, 112:1886-1893.
27. Bali P., Pranpat M., Bradner J., Balasis M., Fiskus W., Guo F., et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 2005, 280:26729-26734.
28. Zilberman Y., Ballestrem C., Carramusa L., Mazitschek R., Khochbin S., Bershadsky A. Regulation of microtubule dynamics by inhibition of the tubulin deacetylase HDAC6. J Cell Sci 2009, 122:3531-3541.
29. Marks P.A., Xu W.S. Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem 2009, 107:600-608.
30. Minucci S., Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006, 6:38-51.
31. Duvic M., Vu J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-Cell lymphoma. Expert Opin Invest Drugs 2007, 16:1111-1120.
32. Campas-Moya C. Romidepsin for the treatment of cutaneous T-cell lymphoma. Drugs Today 2009, 45:787-795.
33. Rodriguez-Gonzalez A., Simms-Waldrip T., Ikeda A.K., Lin T., Lomenick B., Aldana Masangkay G., et al. Tubacin, an inhibitor of HDAC6, induces apoptosis of acute lymphoblastic leukemia cells in vitro and in vivo through a Na+/K+ATPase-dependent pathway. Blood 2008, 112:1923. (abstract).
34. Boyault C., Sadoul K., Pabion M., Khochbin S. HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination. Oncogene 2007, 26:5468-5476.
35. Bazzaro M., Lin Z., Santillan A., Lee M.K., Wang M.C., Chan K.C., et al. Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor. Clin Cancer Res 2008, 14:7340-7347.